Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Total Stockholders Equity : HK$996.3 Mil (As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Shenzhen Neptunus Interlong Bio-Technique Co Total Stockholders Equity?

Shenzhen Neptunus Interlong Bio-Technique Co's Total Stockholders Equity for the quarter that ended in Dec. 2024 was HK$996.3 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Shenzhen Neptunus Interlong Bio-Technique Co's Book Value per Share for the quarter that ended in Dec. 2024 was HK$0.59. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Shenzhen Neptunus Interlong Bio-Technique Co's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.11.

Shenzhen Neptunus Interlong Bio-Technique Co Total Stockholders Equity Historical Data

The historical data trend for Shenzhen Neptunus Interlong Bio-Technique Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Neptunus Interlong Bio-Technique Co Total Stockholders Equity Chart

Shenzhen Neptunus Interlong Bio-Technique Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

940.92

1,015.94

987.22

993.34

996.33

Shenzhen Neptunus Interlong Bio-Technique Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															999.63	-	993.34	1,018.49	996.33

Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Shenzhen Neptunus Interlong Bio-Technique Co's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(996.333	-	0)	/	1678.000
	=	0.59

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Shenzhen Neptunus Interlong Bio-Technique Co's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(106.927	+	5.638)	/	996.333
	=	0.11

Shenzhen Neptunus Interlong Bio-Technique Co Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Shenzhen Neptunus Interlong Bio-Technique Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Neptunus Interlong Bio-Technique Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Neptunus Interlong Bio-Technique Co Ltd (HKSE:08329) » Definitions » Total Stockholders Equity

Traded in Other Exchanges

N/A

Address

979 King’s Road, 43rd Floor, One Taikoo Place, Quarry Bay, Hong Kong, HKG

Website

https://www.interlong.com

Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.

Shenzhen Neptunus Interlong Bio-Technique Co Headlines

No Headlines